Foamix Pharmaceuticals to Present at the Cantor Global Healthcare Conference

REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will present a corporate overview and business update at the Cantor Global Healthcare Conference on Thursday, October 3, 2019 at the InterContinental New York Barclay Hotel in New York City.

Cantor Global Healthcare Conference

About Foamix
Foamix is a specialty pharmaceutical company working to solve some of today’s most difficult therapeutic challenges in dermatology and beyond.

With expertise in topical medicine innovation as a springboard, the company is working to develop and commercialize solutions that were long thought impossible, including the world’s first topical minocycline. Its proprietary Molecule Stabilizing Technology (MST™) is utilized in the company’s dermatology products in late stage development: FMX101 for the potential treatment of moderate-to-severe acne and FMX103 for the potential treatment of moderate-to-severe papulopustular rosacea.

Foamix is a different type of specialty pharmaceutical company by design, driven to see the solutions, overcome barriers in all aspects of business, and reimagine what’s possible for conditions with high unmet needs.

For more information, visit www.foamix.com.